Pivot Bio
Pivot Bio raises $430M Series D at $2B valuation
Quick Facts
Pivot Bio: Series D Funding Round
Pivot Bio has successfully raised $430M in Series D funding, reaching a valuation of $2B.
Company Overview
Nitrogen-producing microbes for agriculture
Funding Details
The Series D round was led by DCVC, with participation from Temasek.
Company Information
- Headquarters: Berkeley, CA
- Founded: 2011
- Employees: 250+
- Category: Biotech
Investment
Pivot Bio plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- DCVC: Verified investor in Series D
- Temasek: Verified investor in Series D
Key Investors
About the Author
Related Company Reports
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...
HorizonStudio Raises $100M Growth to Transform Biotech
HorizonStudio has secured $100M Growth in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
StreamData Raises $15M Seed to Transform Biotech
StreamData has secured $15M Seed in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
